$38.64
0.83[2.20%]
At close: Apr 19
$38.64
0[0.00%]
After Hours: 4:20PM EDT
Halozyme Therapeutics
(NASDAQ:HALO)Halozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions
Halozyme Therapeutics Inc has a consensus price target of $48.47, established from looking at the 46 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Benchmark, and TD Cowen on April 17, 2024, April 16, 2024, and February 29, 2024. With an average price target of $51.33 between HC Wainwright & Co., Benchmark, and TD Cowen, there's an implied 32.85% upside for Halozyme Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Benchmark
TD Cowen
JMP Securities
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Halozyme Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 29.4% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 29.4% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 39.75% | TD Cowen | Brendan Smith | → $54 | Initiates | → Outperform | Get Alert |
| 02/21/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 86.34% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/21/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 29.4% | HC Wainwright & Co. | Mitchell Kapoor | $48 → $50 | Maintains | Buy | Get Alert |
| 01/19/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 29.4% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/19/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 24.22% | HC Wainwright & Co. | Mitchell Kapoor | → $48 | Reiterates | Buy → Buy | Get Alert |
| 01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 86.34% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 3.52% | Goldman Sachs | Graig Suvannavejh | $45 → $40 | Maintains | Neutral | Get Alert |
| 01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 24.22% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $48 | Maintains | Buy | Get Alert |
| 12/26/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 52.69% | Morgan Stanley | Vikram Purohit | $61 → $59 | Maintains | Overweight | Get Alert |
| 10/20/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 29.4% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 10/19/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 57.87% | HC Wainwright & Co. | Mitchell Kapoor | $60 → $61 | Maintains | Buy | Get Alert |
| 10/09/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 55.28% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 55.28% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 55.28% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 55.28% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $60 | Maintains | Buy | Get Alert |
| 08/10/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 57.87% | Morgan Stanley | Vikram Purohit | $60 → $61 | Maintains | Overweight | Get Alert |
| 07/24/2023 | HALO | Buy Now | Halozyme Therapeutics | $38.64 | 57.87% | HC Wainwright & Co. | Mitchell Kapoor | → $61 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Halozyme Therapeutics (HALO)?
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by HC Wainwright & Co. on April 17, 2024. The analyst firm set a price target for $50.00 expecting HALO to rise to within 12 months (a possible 29.40% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Halozyme Therapeutics (HALO)?
The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by HC Wainwright & Co., and Halozyme Therapeutics reiterated their buy rating.
When was the last upgrade for Halozyme Therapeutics (HALO)?
The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.
When was the last downgrade for Halozyme Therapeutics (HALO)?
The last downgrade for Halozyme Therapeutics Inc happened on July 24, 2023 when Goldman Sachs changed their price target from $43 to $45 for Halozyme Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Halozyme Therapeutics (HALO) correct?
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $0.00 to $50.00. The current price Halozyme Therapeutics (HALO) is trading at is $38.64, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.